| Literature DB >> 27873483 |
B Khan1, L G Singer1, L B Lilly2, C Chaparro1, T Martinu1, S Juvet1, M Pipkin1, T K Waddell1, S Keshavjee1, A Humar2, M Cypel1.
Abstract
Lung transplantation using RNA+ hepatitis C (HCV+) donors to seronegative recipients is not currently performed due to the very high risk of transmission. Previous reports have shown poor survival when this practice was applied. The emergence of new direct-acting antiviral drugs (DAA) suggests a high chance of sustained virologic response in immunocompetent patients. We report here successful transplantation of lungs from HCV+ donor to HCV- recipient. The recipient was an HCV- patient with chronic lung allograft dysfunction. Viral transmission occurred early posttransplant but excellent clinical outcomes were observed including elimination of HCV after 12 weeks of treatment using DAAs.Entities:
Keywords: clinical research/practice; complication: infectious; donors and donation: donor-derived infections; donors and donation: extended criteria; infectious disease; lung disease; lung transplantation/pulmonology; organ procurement and allocation; translational research/science
Mesh：
Year: 2017 PMID： 27873483 DOI： 10.1111/ajt.14137
Source DB: PubMed Journal: Am J Transplant ISSN： 1600-6135 Impact factor: 8.086